Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control AdenocarcinomaImmunity, 2016
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target ToxicityMolecular Therapy, 2013
- A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)OncoImmunology, 2012
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Comparative Immunohistochemical Study of MUC1 and Carbohydrate Antigens in Breast Benign Disease and Normal Mammary GlandApplied Immunohistochemistry & Molecular Morphology, 2010
- Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen ReceptorThe Journal of Immunology, 2008
- Mucin-type O-glycosylation and its potential use in drug and vaccine developmentBiochimica et Biophysica Acta (BBA) - General Subjects, 2008
- A Mutant Chaperone Converts a Wild-Type Protein into a Tumor-Specific AntigenScience, 2006
- The Relative Activities of the C2GnT1 and ST3Gal-I Glycosyltransferases Determine O-Glycan Structure and Expression of a Tumor-associated Epitope on MUC1Journal of Biological Chemistry, 2001